Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. [electronic resource]
Producer: 20121226Description: 2356-2362 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Disease-Free Survival
- Female
- Humans
- Immunization, Passive
- Induction Chemotherapy
- Kaplan-Meier Estimate
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Rituximab
- Severity of Illness Index
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.